<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The purpose of this study was to determine whether a low-dose β-blocker, in combination with <z:chebi fb="0" ids="50693">milrinone</z:chebi>, improves cardiac function in <z:hpo ids='HP_0011009'>acute</z:hpo> decompensated <z:hpo ids='HP_0001635'>heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ADHF</z:e>) with <z:hpo ids='HP_0001649'>tachycardia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS AND RESULTS: Twenty <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ADHF</z:e> patients (New York Heart Association classification III, n=1, and IV, n=19; heart rate [HR], 107±12 beats/min; left ventricular ejection fraction, 24±7%; cardiac index [CI], 2.2±0.6 L·min(-1)·m(-2); pulmonary capillary wedge pressure [PCWP], 26±8 mmHg) were enrolled in this study </plain></SENT>
<SENT sid="2" pm="."><plain>The patients first underwent conventional therapy with <z:chebi fb="0" ids="50693">milrinone</z:chebi>, <z:chebi fb="1" ids="35620">vasodilators</z:chebi> and <z:chebi fb="40" ids="35498">diuretics</z:chebi>; landiolol (1.5-6.0 µg·kg(-1)·min(-1); i.v.), which is an ultra-short-acting β(1)-selective blocker, was then added to the treatment regimen to study its effect on hemodynamics </plain></SENT>
<SENT sid="3" pm="."><plain>Low-dose landiolol (1.5 µg·kg(-1)·min(-1)) significantly reduced HR by 11% without changing blood pressure (BP) and CI, whereas higher doses (≥3.0 µg·kg(-1)·min(-1)) tended to decrease BP and CI while increasing PCWP and systemic vascular resistance </plain></SENT>
<SENT sid="4" pm="."><plain>After treatment with landiolol (1.5 µg·kg(-1)·min(-1)), hemodynamic parameters such as PCWP, <z:hpo ids='HP_0001297'>stroke</z:hpo> volume index, SvO(2), rate pressure product, filling time/RR, E/e', and Tei index were significantly improved </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: A low-dose β-blocker in combination with <z:chebi fb="0" ids="50693">milrinone</z:chebi> improved cardiac function in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ADHF</z:e> patients with <z:hpo ids='HP_0001649'>tachycardia</z:hpo>; therefore, it may be considered as an adjunct therapy for use when standard therapy with <z:chebi fb="0" ids="50693">milrinone</z:chebi> is not effective at slowing HR </plain></SENT>
</text></document>